Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Adamas reports results of phase III study of ADS-5102 in MS with walking impairment

Dec. 18, 2019

Pilot clinical results for ondansetron in patients with bipolar disorder and alcohol dependence

Dec. 18, 2019

New analgesics identified at CerSci Therapeutics

Dec. 18, 2019

Mouse model devised to understand the potential of autophagy enhancers in treating ALS

Dec. 18, 2019

Psychiatric risk genes can have distinct effects in different disorders

Dec. 18, 2019

Antisense Therapeutics plans to advance ATL-1102 into phase IIb for DMD

Dec. 17, 2019

Tonix to advance development of TNX-601 CR for depression and PTSD

Dec. 17, 2019

Phase III GEMINI study of AXS-05 in MDD achieves primary endpoint

Dec. 17, 2019

Allopregnanolone affects metabolic and lipid pathways in Alzheimer's disease

Dec. 17, 2019

Wave Life Sciences discontinues development of suvodirsen for DMD

Dec. 16, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...